Replies to post #108323 on Biotech Values

[mcbio]

M118 needs to complete one or more phase-2b studies before embarking on phase-3, so what we’re talking about is the cumulative development cost for phase-2b and phase-3.

Do you have any ballpark guesstimate on how much such remaining trials would cost? $100 million? $200 million? Much more?

[mcbio]

Re: MNTA/M118 co-development

Quote:
--------------------------------------------------------------------------------
So how about some arrangement where MNTA agrees to fund a portion of the costs of Phase-3 trials (say 25%) with the partner taking on the rest and the two parties pro-rating the split of any potential revenues accordingly.
--------------------------------------------------------------------------------

This is likely the kind of deal that’s being discussed. I think 25% is close to the upper limit of what MNTA is willing to fund.

M118 needs to complete one or more phase-2b studies before embarking on phase-3, so what we’re talking about is the cumulative development cost for phase-2b and phase-3.

At about the 22 minute mark of MNTA's Credit Suisse presentation today, where there was in fact considerable more discussion surrounding a generic Lovenox than what was heard during TEVA's presentation yesterday, Rick Shea indicates that with the additional financial resources, MNTA thinks it can "find partners where we can co-fund the next phase of study" for M118.